Progressively Reducing Regulatory Burden
Journal Title: The AAPS Journal - Year 2014, Vol 16, Issue 4
Abstract
Principles of dissolution science have been applied to allow waiver of in vivo bioequivalence studies for oral immediate release solid dosage forms, providing certain stipulations are met. This approach reduces regulatory burden without sacrificing product quality and performance requirements that assure continuing equivalence. These principles are broadly applicable to other dosage forms and routes of administration. In this article, we postulate a further opportunity, which relies on a determination of “optimal performance” for nonsolution orally administered drug products. The determination can be applied to certain highly soluble and rapidly dissolving drug products without further study, paving the way possibly for even further reductions in regulatory burden.
Authors and Affiliations
Vinod P. Shah, Todd L. Cecil, Srini V. Srinivasan, Roger L. Williams
Keywords
Related Articles
- EP ID EP681696
- DOI 10.1208/s12248-014-9601-z
- Views 78
- Downloads 0
Pharmacokinetics, mass balance, and tissue distribution of a novel DNA alkylating agent, VNP40101M, in rats
VNP40101M (1,2-Bis(methylsulfonyl)-1-(2-chloroethyl)-2-[(2 methylamino)carbonyl] hydrazine), a novel DNA alkylating agent, is currently under clinical development for the treatment of cancer in Phase I clinical trials. T...
Evaluation of a Catenary PBPK Model for Predicting the In Vivo Disposition of mAbs Engineered for High-Affinity Binding to FcRn
The online version of this article (doi:10.1208/s12248-012-9395-9) contains supplementary material, which is available to authorized users.
Use of Partial Area under the Curve Metrics to Assess Bioequivalence of Methylphenidate Multiphasic Modified Release Formulations
Pharmacokinetics of Orally Inhaled Drug Products
The presentations at the Orlando Inhalation Conference on pharmacokinetic (PK) studies indicated that PK is the most sensitive methodology for detecting formulation differences of oral inhaled drug products (OIDPs) that...
Reliability and Extension of Quantitative Prediction of CYP3A4-Mediated Drug Interactions Based on Clinical Data
The online version of this article (doi:10.1208/s12248-014-9663-y) contains supplementary material, which is available to authorized users.